Global HIV Associated Lipodystrophy Syndrome Treatment Market Growth (Status and Outlook) 2025-2031

September 2025 | 92 pages | ID: G4233B9322DEN
LP Information

Abstracts

According to this study, the global HIV Associated Lipodystrophy Syndrome Treatment market size will reach US$ million by 2031.

Lipodystrophy syndrome groups together three clinical conditions characterized by abnormal body fat distribution: lipoatrophy, lipoaccumulation and a mixed syndrome.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LPI (LP Information)' newest research report, the “HIV Associated Lipodystrophy Syndrome Treatment Industry Forecast” looks at past sales and reviews total world HIV Associated Lipodystrophy Syndrome Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected HIV Associated Lipodystrophy Syndrome Treatment sales for 2025 through 2031. With HIV Associated Lipodystrophy Syndrome Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world HIV Associated Lipodystrophy Syndrome Treatment industry.

This Insight Report provides a comprehensive analysis of the global HIV Associated Lipodystrophy Syndrome Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on HIV Associated Lipodystrophy Syndrome Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global HIV Associated Lipodystrophy Syndrome Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for HIV Associated Lipodystrophy Syndrome Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global HIV Associated Lipodystrophy Syndrome Treatment.

This report presents a comprehensive overview, market shares, and growth opportunities of HIV Associated Lipodystrophy Syndrome Treatment market by product type, application, key players and key regions and countries.

Segmentation by Type:

• Specific Drug Treatment
• Cosmetic Corrective Treatment

Segmentation by Application:

• Hospital
• Specialist Clinic
• Others

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Gilead Sciences
• Amgen
• Abbott
• AstraZeneca
• AbbVie
• GlaxoSmithKline
• Alfa Wassermann SPA
• Theratechnologies
• Bristol-Myers Squibb

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global HIV Associated Lipodystrophy Syndrome Treatment Market Size (2020-2031)
  2.1.2 HIV Associated Lipodystrophy Syndrome Treatment Market Size CAGR by Region (2020 VS 2024 VS 2031)
  2.1.3 World Current & Future Analysis for HIV Associated Lipodystrophy Syndrome Treatment by Country/Region (2020, 2024 & 2031)
2.2 HIV Associated Lipodystrophy Syndrome Treatment Segment by Type
  2.2.1 Specific Drug Treatment
  2.2.2 Cosmetic Corrective Treatment
2.3 HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type
  2.3.1 HIV Associated Lipodystrophy Syndrome Treatment Market Size CAGR by Type (2020 VS 2024 VS 2031)
  2.3.2 Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share by Type (2020-2025)
2.4 HIV Associated Lipodystrophy Syndrome Treatment Segment by Application
  2.4.1 Hospital
  2.4.2 Specialist Clinic
  2.4.3 Others
2.5 HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application
  2.5.1 HIV Associated Lipodystrophy Syndrome Treatment Market Size CAGR by Application (2020 VS 2024 VS 2031)
  2.5.2 Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share by Application (2020-2025)

3 HIV ASSOCIATED LIPODYSTROPHY SYNDROME TREATMENT MARKET SIZE BY PLAYER

3.1 HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share by Player
  3.1.1 Global HIV Associated Lipodystrophy Syndrome Treatment Revenue by Player (2020-2025)
  3.1.2 Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share by Player (2020-2025)
3.2 Global HIV Associated Lipodystrophy Syndrome Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 HIV ASSOCIATED LIPODYSTROPHY SYNDROME TREATMENT BY REGION

4.1 HIV Associated Lipodystrophy Syndrome Treatment Market Size by Region (2020-2025)
4.2 Global HIV Associated Lipodystrophy Syndrome Treatment Annual Revenue by Country/Region (2020-2025)
4.3 Americas HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth (2020-2025)
4.4 APAC HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth (2020-2025)
4.5 Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth (2020-2025)
4.6 Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth (2020-2025)

5 AMERICAS

5.1 Americas HIV Associated Lipodystrophy Syndrome Treatment Market Size by Country (2020-2025)
5.2 Americas HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2020-2025)
5.3 Americas HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC HIV Associated Lipodystrophy Syndrome Treatment Market Size by Region (2020-2025)
6.2 APAC HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2020-2025)
6.3 APAC HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Country (2020-2025)
7.2 Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2020-2025)
7.3 Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment by Region (2020-2025)
8.2 Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2020-2025)
8.3 Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL HIV ASSOCIATED LIPODYSTROPHY SYNDROME TREATMENT MARKET FORECAST

10.1 Global HIV Associated Lipodystrophy Syndrome Treatment Forecast by Region (2026-2031)
  10.1.1 Global HIV Associated Lipodystrophy Syndrome Treatment Forecast by Region (2026-2031)
  10.1.2 Americas HIV Associated Lipodystrophy Syndrome Treatment Forecast
  10.1.3 APAC HIV Associated Lipodystrophy Syndrome Treatment Forecast
  10.1.4 Europe HIV Associated Lipodystrophy Syndrome Treatment Forecast
  10.1.5 Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Forecast
10.2 Americas HIV Associated Lipodystrophy Syndrome Treatment Forecast by Country (2026-2031)
  10.2.1 United States Market HIV Associated Lipodystrophy Syndrome Treatment Forecast
  10.2.2 Canada Market HIV Associated Lipodystrophy Syndrome Treatment Forecast
  10.2.3 Mexico Market HIV Associated Lipodystrophy Syndrome Treatment Forecast
  10.2.4 Brazil Market HIV Associated Lipodystrophy Syndrome Treatment Forecast
10.3 APAC HIV Associated Lipodystrophy Syndrome Treatment Forecast by Region (2026-2031)
  10.3.1 China HIV Associated Lipodystrophy Syndrome Treatment Market Forecast
  10.3.2 Japan Market HIV Associated Lipodystrophy Syndrome Treatment Forecast
  10.3.3 Korea Market HIV Associated Lipodystrophy Syndrome Treatment Forecast
  10.3.4 Southeast Asia Market HIV Associated Lipodystrophy Syndrome Treatment Forecast
  10.3.5 India Market HIV Associated Lipodystrophy Syndrome Treatment Forecast
  10.3.6 Australia Market HIV Associated Lipodystrophy Syndrome Treatment Forecast
10.4 Europe HIV Associated Lipodystrophy Syndrome Treatment Forecast by Country (2026-2031)
  10.4.1 Germany Market HIV Associated Lipodystrophy Syndrome Treatment Forecast
  10.4.2 France Market HIV Associated Lipodystrophy Syndrome Treatment Forecast
  10.4.3 UK Market HIV Associated Lipodystrophy Syndrome Treatment Forecast
  10.4.4 Italy Market HIV Associated Lipodystrophy Syndrome Treatment Forecast
  10.4.5 Russia Market HIV Associated Lipodystrophy Syndrome Treatment Forecast
10.5 Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Forecast by Region (2026-2031)
  10.5.1 Egypt Market HIV Associated Lipodystrophy Syndrome Treatment Forecast
  10.5.2 South Africa Market HIV Associated Lipodystrophy Syndrome Treatment Forecast
  10.5.3 Israel Market HIV Associated Lipodystrophy Syndrome Treatment Forecast
  10.5.4 Turkey Market HIV Associated Lipodystrophy Syndrome Treatment Forecast
10.6 Global HIV Associated Lipodystrophy Syndrome Treatment Forecast by Type (2026-2031)
10.7 Global HIV Associated Lipodystrophy Syndrome Treatment Forecast by Application (2026-2031)
  10.7.1 GCC Countries Market HIV Associated Lipodystrophy Syndrome Treatment Forecast

11 KEY PLAYERS ANALYSIS

11.1 Gilead Sciences
  11.1.1 Gilead Sciences Company Information
  11.1.2 Gilead Sciences HIV Associated Lipodystrophy Syndrome Treatment Product Offered
  11.1.3 Gilead Sciences HIV Associated Lipodystrophy Syndrome Treatment Revenue, Gross Margin and Market Share (2020-2025)
  11.1.4 Gilead Sciences Main Business Overview
  11.1.5 Gilead Sciences Latest Developments
11.2 Amgen
  11.2.1 Amgen Company Information
  11.2.2 Amgen HIV Associated Lipodystrophy Syndrome Treatment Product Offered
  11.2.3 Amgen HIV Associated Lipodystrophy Syndrome Treatment Revenue, Gross Margin and Market Share (2020-2025)
  11.2.4 Amgen Main Business Overview
  11.2.5 Amgen Latest Developments
11.3 Abbott
  11.3.1 Abbott Company Information
  11.3.2 Abbott HIV Associated Lipodystrophy Syndrome Treatment Product Offered
  11.3.3 Abbott HIV Associated Lipodystrophy Syndrome Treatment Revenue, Gross Margin and Market Share (2020-2025)
  11.3.4 Abbott Main Business Overview
  11.3.5 Abbott Latest Developments
11.4 AstraZeneca
  11.4.1 AstraZeneca Company Information
  11.4.2 AstraZeneca HIV Associated Lipodystrophy Syndrome Treatment Product Offered
  11.4.3 AstraZeneca HIV Associated Lipodystrophy Syndrome Treatment Revenue, Gross Margin and Market Share (2020-2025)
  11.4.4 AstraZeneca Main Business Overview
  11.4.5 AstraZeneca Latest Developments
11.5 AbbVie
  11.5.1 AbbVie Company Information
  11.5.2 AbbVie HIV Associated Lipodystrophy Syndrome Treatment Product Offered
  11.5.3 AbbVie HIV Associated Lipodystrophy Syndrome Treatment Revenue, Gross Margin and Market Share (2020-2025)
  11.5.4 AbbVie Main Business Overview
  11.5.5 AbbVie Latest Developments
11.6 GlaxoSmithKline
  11.6.1 GlaxoSmithKline Company Information
  11.6.2 GlaxoSmithKline HIV Associated Lipodystrophy Syndrome Treatment Product Offered
  11.6.3 GlaxoSmithKline HIV Associated Lipodystrophy Syndrome Treatment Revenue, Gross Margin and Market Share (2020-2025)
  11.6.4 GlaxoSmithKline Main Business Overview
  11.6.5 GlaxoSmithKline Latest Developments
11.7 Alfa Wassermann SPA
  11.7.1 Alfa Wassermann SPA Company Information
  11.7.2 Alfa Wassermann SPA HIV Associated Lipodystrophy Syndrome Treatment Product Offered
  11.7.3 Alfa Wassermann SPA HIV Associated Lipodystrophy Syndrome Treatment Revenue, Gross Margin and Market Share (2020-2025)
  11.7.4 Alfa Wassermann SPA Main Business Overview
  11.7.5 Alfa Wassermann SPA Latest Developments
11.8 Theratechnologies
  11.8.1 Theratechnologies Company Information
  11.8.2 Theratechnologies HIV Associated Lipodystrophy Syndrome Treatment Product Offered
  11.8.3 Theratechnologies HIV Associated Lipodystrophy Syndrome Treatment Revenue, Gross Margin and Market Share (2020-2025)
  11.8.4 Theratechnologies Main Business Overview
  11.8.5 Theratechnologies Latest Developments
11.9 Bristol-Myers Squibb
  11.9.1 Bristol-Myers Squibb Company Information
  11.9.2 Bristol-Myers Squibb HIV Associated Lipodystrophy Syndrome Treatment Product Offered
  11.9.3 Bristol-Myers Squibb HIV Associated Lipodystrophy Syndrome Treatment Revenue, Gross Margin and Market Share (2020-2025)
  11.9.4 Bristol-Myers Squibb Main Business Overview
  11.9.5 Bristol-Myers Squibb Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. HIV Associated Lipodystrophy Syndrome Treatment Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. HIV Associated Lipodystrophy Syndrome Treatment Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Specific Drug Treatment
Table 4. Major Players of Cosmetic Corrective Treatment
Table 5. HIV Associated Lipodystrophy Syndrome Treatment Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 6. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2020-2025) & ($ millions)
Table 7. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share by Type (2020-2025)
Table 8. HIV Associated Lipodystrophy Syndrome Treatment Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 9. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2020-2025) & ($ millions)
Table 10. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share by Application (2020-2025)
Table 11. Global HIV Associated Lipodystrophy Syndrome Treatment Revenue by Player (2020-2025) & ($ millions)
Table 12. Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share by Player (2020-2025)
Table 13. HIV Associated Lipodystrophy Syndrome Treatment Key Players Head office and Products Offered
Table 14. HIV Associated Lipodystrophy Syndrome Treatment Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size by Region (2020-2025) & ($ millions)
Table 18. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share by Region (2020-2025)
Table 19. Global HIV Associated Lipodystrophy Syndrome Treatment Revenue by Country/Region (2020-2025) & ($ millions)
Table 20. Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share by Country/Region (2020-2025)
Table 21. Americas HIV Associated Lipodystrophy Syndrome Treatment Market Size by Country (2020-2025) & ($ millions)
Table 22. Americas HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share by Country (2020-2025)
Table 23. Americas HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2020-2025) & ($ millions)
Table 24. Americas HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share by Type (2020-2025)
Table 25. Americas HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2020-2025) & ($ millions)
Table 26. Americas HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share by Application (2020-2025)
Table 27. APAC HIV Associated Lipodystrophy Syndrome Treatment Market Size by Region (2020-2025) & ($ millions)
Table 28. APAC HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share by Region (2020-2025)
Table 29. APAC HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2020-2025) & ($ millions)
Table 30. APAC HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2020-2025) & ($ millions)
Table 31. Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Country (2020-2025) & ($ millions)
Table 32. Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share by Country (2020-2025)
Table 33. Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2020-2025) & ($ millions)
Table 34. Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2020-2025) & ($ millions)
Table 35. Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size by Region (2020-2025) & ($ millions)
Table 36. Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2020-2025) & ($ millions)
Table 37. Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2020-2025) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of HIV Associated Lipodystrophy Syndrome Treatment
Table 39. Key Market Challenges & Risks of HIV Associated Lipodystrophy Syndrome Treatment
Table 40. Key Industry Trends of HIV Associated Lipodystrophy Syndrome Treatment
Table 41. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Region (2026-2031) & ($ millions)
Table 42. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share Forecast by Region (2026-2031)
Table 43. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Type (2026-2031) & ($ millions)
Table 44. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Forecast by Application (2026-2031) & ($ millions)
Table 45. Gilead Sciences Details, Company Type, HIV Associated Lipodystrophy Syndrome Treatment Area Served and Its Competitors
Table 46. Gilead Sciences HIV Associated Lipodystrophy Syndrome Treatment Product Offered
Table 47. Gilead Sciences HIV Associated Lipodystrophy Syndrome Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 48. Gilead Sciences Main Business
Table 49. Gilead Sciences Latest Developments
Table 50. Amgen Details, Company Type, HIV Associated Lipodystrophy Syndrome Treatment Area Served and Its Competitors
Table 51. Amgen HIV Associated Lipodystrophy Syndrome Treatment Product Offered
Table 52. Amgen HIV Associated Lipodystrophy Syndrome Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 53. Amgen Main Business
Table 54. Amgen Latest Developments
Table 55. Abbott Details, Company Type, HIV Associated Lipodystrophy Syndrome Treatment Area Served and Its Competitors
Table 56. Abbott HIV Associated Lipodystrophy Syndrome Treatment Product Offered
Table 57. Abbott HIV Associated Lipodystrophy Syndrome Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 58. Abbott Main Business
Table 59. Abbott Latest Developments
Table 60. AstraZeneca Details, Company Type, HIV Associated Lipodystrophy Syndrome Treatment Area Served and Its Competitors
Table 61. AstraZeneca HIV Associated Lipodystrophy Syndrome Treatment Product Offered
Table 62. AstraZeneca HIV Associated Lipodystrophy Syndrome Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 63. AstraZeneca Main Business
Table 64. AstraZeneca Latest Developments
Table 65. AbbVie Details, Company Type, HIV Associated Lipodystrophy Syndrome Treatment Area Served and Its Competitors
Table 66. AbbVie HIV Associated Lipodystrophy Syndrome Treatment Product Offered
Table 67. AbbVie HIV Associated Lipodystrophy Syndrome Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 68. AbbVie Main Business
Table 69. AbbVie Latest Developments
Table 70. GlaxoSmithKline Details, Company Type, HIV Associated Lipodystrophy Syndrome Treatment Area Served and Its Competitors
Table 71. GlaxoSmithKline HIV Associated Lipodystrophy Syndrome Treatment Product Offered
Table 72. GlaxoSmithKline HIV Associated Lipodystrophy Syndrome Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 73. GlaxoSmithKline Main Business
Table 74. GlaxoSmithKline Latest Developments
Table 75. Alfa Wassermann SPA Details, Company Type, HIV Associated Lipodystrophy Syndrome Treatment Area Served and Its Competitors
Table 76. Alfa Wassermann SPA HIV Associated Lipodystrophy Syndrome Treatment Product Offered
Table 77. Alfa Wassermann SPA HIV Associated Lipodystrophy Syndrome Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 78. Alfa Wassermann SPA Main Business
Table 79. Alfa Wassermann SPA Latest Developments
Table 80. Theratechnologies Details, Company Type, HIV Associated Lipodystrophy Syndrome Treatment Area Served and Its Competitors
Table 81. Theratechnologies HIV Associated Lipodystrophy Syndrome Treatment Product Offered
Table 82. Theratechnologies HIV Associated Lipodystrophy Syndrome Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 83. Theratechnologies Main Business
Table 84. Theratechnologies Latest Developments
Table 85. Bristol-Myers Squibb Details, Company Type, HIV Associated Lipodystrophy Syndrome Treatment Area Served and Its Competitors
Table 86. Bristol-Myers Squibb HIV Associated Lipodystrophy Syndrome Treatment Product Offered
Table 87. Bristol-Myers Squibb HIV Associated Lipodystrophy Syndrome Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 88. Bristol-Myers Squibb Main Business
Table 89. Bristol-Myers Squibb Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. HIV Associated Lipodystrophy Syndrome Treatment Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. HIV Associated Lipodystrophy Syndrome Treatment Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. HIV Associated Lipodystrophy Syndrome Treatment Sales Market Share by Country/Region (2024)
Figure 8. HIV Associated Lipodystrophy Syndrome Treatment Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share by Type in 2024
Figure 10. HIV Associated Lipodystrophy Syndrome Treatment in Hospital
Figure 11. Global HIV Associated Lipodystrophy Syndrome Treatment Market: Hospital (2020-2025) & ($ millions)
Figure 12. HIV Associated Lipodystrophy Syndrome Treatment in Specialist Clinic
Figure 13. Global HIV Associated Lipodystrophy Syndrome Treatment Market: Specialist Clinic (2020-2025) & ($ millions)
Figure 14. HIV Associated Lipodystrophy Syndrome Treatment in Others
Figure 15. Global HIV Associated Lipodystrophy Syndrome Treatment Market: Others (2020-2025) & ($ millions)
Figure 16. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share by Application in 2024
Figure 17. Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share by Player in 2024
Figure 18. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share by Region (2020-2025)
Figure 19. Americas HIV Associated Lipodystrophy Syndrome Treatment Market Size 2020-2025 ($ millions)
Figure 20. APAC HIV Associated Lipodystrophy Syndrome Treatment Market Size 2020-2025 ($ millions)
Figure 21. Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size 2020-2025 ($ millions)
Figure 23. Americas HIV Associated Lipodystrophy Syndrome Treatment Value Market Share by Country in 2024
Figure 24. United States HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share by Region in 2024
Figure 29. APAC HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share by Type (2020-2025)
Figure 30. APAC HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share by Application (2020-2025)
Figure 31. China HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth 2020-2025 ($ millions)
Figure 35. India HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share by Country in 2024
Figure 38. Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share by Type (2020-2025)
Figure 39. Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share by Application (2020-2025)
Figure 40. Germany HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth 2020-2025 ($ millions)
Figure 41. France HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth 2020-2025 ($ millions)
Figure 42. UK HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share by Type (2020-2025)
Figure 47. Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share by Application (2020-2025)
Figure 48. Egypt HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth 2020-2025 ($ millions)
Figure 51. Turkey HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas HIV Associated Lipodystrophy Syndrome Treatment Market Size 2026-2031 ($ millions)
Figure 54. APAC HIV Associated Lipodystrophy Syndrome Treatment Market Size 2026-2031 ($ millions)
Figure 55. Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size 2026-2031 ($ millions)
Figure 57. United States HIV Associated Lipodystrophy Syndrome Treatment Market Size 2026-2031 ($ millions)
Figure 58. Canada HIV Associated Lipodystrophy Syndrome Treatment Market Size 2026-2031 ($ millions)
Figure 59. Mexico HIV Associated Lipodystrophy Syndrome Treatment Market Size 2026-2031 ($ millions)
Figure 60. Brazil HIV Associated Lipodystrophy Syndrome Treatment Market Size 2026-2031 ($ millions)
Figure 61. China HIV Associated Lipodystrophy Syndrome Treatment Market Size 2026-2031 ($ millions)
Figure 62. Japan HIV Associated Lipodystrophy Syndrome Treatment Market Size 2026-2031 ($ millions)
Figure 63. Korea HIV Associated Lipodystrophy Syndrome Treatment Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia HIV Associated Lipodystrophy Syndrome Treatment Market Size 2026-2031 ($ millions)
Figure 65. India HIV Associated Lipodystrophy Syndrome Treatment Market Size 2026-2031 ($ millions)
Figure 66. Australia HIV Associated Lipodystrophy Syndrome Treatment Market Size 2026-2031 ($ millions)
Figure 67. Germany HIV Associated Lipodystrophy Syndrome Treatment Market Size 2026-2031 ($ millions)
Figure 68. France HIV Associated Lipodystrophy Syndrome Treatment Market Size 2026-2031 ($ millions)
Figure 69. UK HIV Associated Lipodystrophy Syndrome Treatment Market Size 2026-2031 ($ millions)
Figure 70. Italy HIV Associated Lipodystrophy Syndrome Treatment Market Size 2026-2031 ($ millions)
Figure 71. Russia HIV Associated Lipodystrophy Syndrome Treatment Market Size 2026-2031 ($ millions)
Figure 72. Egypt HIV Associated Lipodystrophy Syndrome Treatment Market Size 2026-2031 ($ millions)
Figure 73. South Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size 2026-2031 ($ millions)
Figure 74. Israel HIV Associated Lipodystrophy Syndrome Treatment Market Size 2026-2031 ($ millions)
Figure 75. Turkey HIV Associated Lipodystrophy Syndrome Treatment Market Size 2026-2031 ($ millions)
Figure 76. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share Forecast by Type (2026-2031)
Figure 77. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Market Share Forecast by Application (2026-2031)
Figure 78. GCC Countries HIV Associated Lipodystrophy Syndrome Treatment Market Size 2026-2031 ($ millions)